Laurus Labs Limited (BOM:540222)

Market Cap	545.58B +89.2%
Revenue (ttm)	67.22B +27.5%
Net Income	8.43B +321.1%
EPS	15.61 +321.7%
Shares Out	n/a
PE Ratio	64.69
Forward PE	56.41
Dividend	1.60 (0.16%)
Ex-Dividend Date	Oct 31, 2025

Volume	74,100
Average Volume	149,444
Open	1,009.65
Previous Close	1,018.90
Day's Range	1,002.00 - 1,021.35
52-Week Range	512.05 - 1,140.90
Beta	n/a
RSI	51.05
Earnings Date	Jan 23, 2026

About Laurus Labs

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. In addition,...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 2005
• Employees: 6,167
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 540222

Financial Performance

In fiscal year 2025, Laurus Labs's revenue was 55.54 billion, an increase of 10.18% compared to the previous year's 50.41 billion. Earnings were 3.58 billion, an increase of 123.18%.